These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 36923402)

  • 1. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies.
    Huang B; Zhang J; Zong W; Chen S; Zong Z; Zeng X; Zhang H
    Front Immunol; 2023; 14():994698. PubMed ID: 36923402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
    Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
    Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid Cells in Glioblastoma Microenvironment.
    De Leo A; Ugolini A; Veglia F
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
    Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunosuppressive microenvironment and immunotherapy in human glioblastoma.
    Zhang X; Zhao L; Zhang H; Zhang Y; Ju H; Wang X; Ren H; Zhu X; Dong Y
    Front Immunol; 2022; 13():1003651. PubMed ID: 36466873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma.
    Shimato S; Anderson LM; Asslaber M; Bruce JN; Canoll P; Anderson DE; Anderson RC
    PLoS One; 2013; 8(10):e77397. PubMed ID: 24130882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Neuro-Oncology.
    Majd N; Dasgupta P; de Groot J
    Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrinsic factors associated with the response to immunotherapy in glioblastoma.
    Bi H; Zhang C
    Cancer Lett; 2021 Jul; 511():47-55. PubMed ID: 33933551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
    Pang L; Khan F; Dunterman M; Chen P
    Trends Pharmacol Sci; 2022 Aug; 43(8):686-700. PubMed ID: 35534356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.
    Pang L; Khan F; Heimberger AB; Chen P
    Trends Cancer; 2022 Oct; 8(10):839-854. PubMed ID: 35624002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.
    Arbab AS; Rashid MH; Angara K; Borin TF; Lin PC; Jain M; Achyut BR
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
    Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
    Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Myeloid Cells in GBM Immunosuppression.
    Lin YJ; Wu CY; Wu JY; Lim M
    Front Immunol; 2022; 13():887781. PubMed ID: 35711434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.